Phase II trial of capecitabine (Xeloda) and lapatinib (Tykerb) as first-line therapy in patients with HER2 [human epidermal growth factor receptor 2]/Neu-overexpressing advanced or metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2017
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 02 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.